The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
However, pharmaceutical companies are the ones kind of that have reached out and they kind of as you know there's there's quite a bit of patent literature that because I was talking about this like a while ago. So I think the Buck Institute has like patents on LBA hydroxybutyrate. There's I would say there's probably about three dozen patents on L now because I've kind of probably attributed to me because I'm talking about the effects.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.